Cargando…

Recent Advances in the Development of Bioreactors for Manufacturing of Adoptive Cell Immunotherapies

Harnessing the human immune system as a foundation for therapeutic technologies capable of recognizing and killing tumor cells has been the central objective of anti-cancer immunotherapy. In recent years, there has been an increasing interest in improving the effectiveness and accessibility of this...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ganeeva, Irina, Zmievskaya, Ekaterina, Valiullina, Aygul, Kudriaeva, Anna, Miftakhova, Regina, Rybalov, Alexey, Bulatov, Emil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9774716/ https://www.ncbi.nlm.nih.gov/pubmed/36551014 http://dx.doi.org/10.3390/bioengineering9120808

Ejemplares similares

Adoptive Immunotherapy beyond CAR T-Cells
por: Titov, Aleksei, et al.
Publicado: (2021)

Knowns and Unknowns about CAR-T Cell Dysfunction
por: Titov, Aleksei, et al.
Publicado: (2022)

Application of CAR-T Cell Therapy beyond Oncology: Autoimmune Diseases and Viral Infections
por: Zmievskaya, Ekaterina, et al.
Publicado: (2021)

Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment
por: Titov, Aleksei, et al.
Publicado: (2020)

Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies
por: Chasov, Vitaly, et al.
Publicado: (2021)

Key Players in the Mutant p53 Team: Small Molecules, Gene Editing, Immunotherapy
por: Chasov, Vitaly, et al.
Publicado: (2020)

Evaluation of CAR-T Cells’ Cytotoxicity against Modified Solid Tumor Cell Lines
por: Valiullina, Aigul Kh., et al.
Publicado: (2023)

Сytotoxic effect of CAR-T cells against modified MCF-7 breast cancer cell line
por: Valiullina, Aigul Kh., et al.
Publicado: (2023)

Neglected, yet significant role of FOXP1 in T-cell quiescence, differentiation and exhaustion
por: Kaminskiy, Yaroslav, et al.
Publicado: (2022)

Small Molecule Modulators of RING-Type E3 Ligases: MDM and Cullin Families as Targets
por: Bulatov, Emil, et al.
Publicado: (2018)

Industrializing Autologous Adoptive Immunotherapies: Manufacturing Advances and Challenges
por: Iyer, Rohin K., et al.
Publicado: (2018)

Recent advances in adoptive cancer immunotherapy in china
por: Zhou, Juhua
Publicado: (2015)

Therapeutic Editing of the TP53 Gene: Is CRISPR/Cas9 an Option?
por: Mirgayazova, Regina, et al.
Publicado: (2020)

Isatin-Schiff base-copper (II) complex induces cell death in p53-positive tumors
por: Bulatov, Emil, et al.
Publicado: (2018)

Adoptive immunotherapies in neuro-oncology: classification, recent advances, and translational challenges
por: Luzzi, Sabino, et al.
Publicado: (2020)

Recent advances in bioreactors for cell-based therapies
por: Stephenson, Makeda, et al.
Publicado: (2018)

Recent Advances in the Prediction of Fouling in Membrane Bioreactors
por: Shi, Yaoke, et al.
Publicado: (2021)

Optimizing the Procedure to Manufacture Clinical-Grade NK Cells for Adoptive Immunotherapy
por: Fernández, Adrián, et al.
Publicado: (2021)

Lymphocyte expansion in bioreactors: upgrading adoptive cell therapy
por: Garcia-Aponte, Oscar Fabian, et al.
Publicado: (2021)

USP7 Inhibitors in Cancer Immunotherapy: Current Status and Perspective
por: Korenev, Georgiy, et al.
Publicado: (2022)

Membrane bioreactors for hospital wastewater treatment: recent advancements in membranes and processes
por: Zhao, Yan, et al.
Publicado: (2021)

Adipose-Derived Mesenchymal Stem Cell (MSC) Immortalization by Modulation of hTERT and TP53 Expression Levels
por: Rakhmatullina, Aigul R., et al.
Publicado: (2023)

Recent Advances in Manufacturing Innovative Stents
por: Beshchasna, Natalia, et al.
Publicado: (2020)

Update on the challenges and recent advances in cancer immunotherapy
por: Baronzio, Gianfranco, et al.
Publicado: (2013)

T Cells and Adoptive Immunotherapy: Recent Developments and Future Prospects in Gastrointestinal Oncology
por: Amedei, Amedeo, et al.
Publicado: (2011)

Induced Pluripotent Stem Cell (iPSC)–Derived Lymphocytes for Adoptive Cell Immunotherapy: Recent Advances and Challenges
por: Nianias, Alexandros, et al.
Publicado: (2019)

The productivity limit of manufacturing blood cell therapy in scalable stirred bioreactors
por: Bayley, Rachel, et al.
Publicado: (2017)

Recent advances in cancer immunotherapy
por: Sun, Weijing
Publicado: (2017)

Recent Advances in Cancer Immunotherapy
por: Suda, Kenichi
Publicado: (2021)

Recent advances in cancer immunotherapy
por: Sun, Qiang, et al.
Publicado: (2021)

Plants as bioreactors: Recent developments and emerging opportunities
por: Sharma, Arun K., et al.
Publicado: (2009)

Manufacturing T cells in hollow fiber membrane bioreactors changes their programming and enhances their potency
por: Yoo, Seung Mi, et al.
Publicado: (2021)

Current status of red blood cell manufacturing in 3D culture and bioreactors
por: Kweon, Soonho, et al.
Publicado: (2023)

Recent Advances and Future Challenges in the Additive Manufacturing of Hydrogels
por: Danek, Chris
Publicado: (2022)

Recent Advances in Metal Powder-Based Additive Manufacturing
por: Wu, Hong, et al.
Publicado: (2023)

Recent advances of additively manufactured noninvasive kinematic biosensors
por: Lee, Jeonghoon, et al.
Publicado: (2023)

Recent Advances in Immunotherapy in Metastatic NSCLC
por: Bansal, Pranshu, et al.
Publicado: (2016)

Recent Advances in Immunotherapy for Hepatocellular Carcinoma
por: Nakano, Shigeharu, et al.
Publicado: (2020)

Cancer immunotherapy: recent advances and challenges
por: Swami, Umang, et al.
Publicado: (2021)

Recent Advances and Challenges in Cancer Immunotherapy
por: Peterson, Chelsea, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cnsacneud99ei36cau1dmq45d5